Literature DB >> 22298086

TCRβ clonality improves diagnostic yield of TCRγ clonality in refractory celiac disease.

Vittorio Perfetti1, Laura Brunetti, Federico Biagi, Rachele Ciccocioppo, Paola I Bianchi, Gino R Corazza.   

Abstract

BACKGROUND: Refractory celiac disease (RCD) is a preneoplastic condition as many patients develop an enteropathy-type T-cell lymphoma, a mature T-cell receptor α-β lymphoma arising in the gut with an ominous outcome. Recently, research focused on a population of intraepithelial intestinal lymphocytes expressing the same lymphoma T-cell receptor variable region (V)γ, as shown by polymerase chain reaction (PCR) analysis and sequencing. Meanwhile, the Biomedicine and Health-2 Concerted Action has made available standardized, highly specific, and sensitive PCR assays not only for Vγ but also for Vβ. GOALS: We verified whether analyzing both rearrangements in duodenal biopsies from RCD patients increases the diagnostic accuracy of this method. STUDY: Duodenal biopsies were analyzed from 15 RCD patients, 21 negative controls, and 2 positive controls (enteropathy-type T-cell lymphoma complicating celiac disease). Multiplex clonality analyses were performed according to the Biomedicine and Health-2 protocols. PCR products were cloned and sequenced.
RESULTS: Monoclonal rearrangements were found in 5/15 samples from patients with RCD (both rearrangements in 2 cases, Vβ only in 2, and only 1 solitary Vγ clonality). Monoclonality was found in 4/8 of the RCD patients who subsequently died, whereas only 1/7 of the patients still alive presented a monoclonal rearrangement. Positive controls revealed both monoclonal rearrangements; rearrangements were not detected in 20 of 21 negative controls. Sequencing of the amplified fragments confirmed the results.
CONCLUSIONS: The combined analysis of both rearrangements allowed recognition of monoclonal populations in otherwise negative patients, with detection rates from 20% (Vγ only) to 33% (Vγ and Vβ), thus raising the likelihood of early identification of RCD patients at high risk of death.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298086     DOI: 10.1097/MCG.0b013e31823eff20

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Optimal strategies to identify aberrant intra-epithelial lymphocytes in refractory coeliac disease.

Authors:  R L J van Wanrooij; D M J Müller; E A Neefjes-Borst; J Meijer; L G Koudstaal; D A M Heideman; H J Bontkes; B M E von Blomberg; G Bouma; C J J Mulder
Journal:  J Clin Immunol       Date:  2014-07-27       Impact factor: 8.317

Review 2.  Refractory celiac disease: from bench to bedside.

Authors:  Georgia Malamut; Bertrand Meresse; Christophe Cellier; Nadine Cerf-Bensussan
Journal:  Semin Immunopathol       Date:  2012-07-19       Impact factor: 9.623

3.  T-cell repertoires in refractory coeliac disease.

Authors:  Julia Ritter; Karin Zimmermann; Korinna Jöhrens; Stefanie Mende; Anke Seegebarth; Britta Siegmund; Steffen Hennig; Kremena Todorova; Andreas Rosenwald; Severin Daum; Michael Hummel; Michael Schumann
Journal:  Gut       Date:  2017-02-10       Impact factor: 23.059

4.  Serum Markers of Refractoriness and Enteropathy-Associated T-Cell Lymphoma in Coeliac Disease.

Authors:  Marco Vincenzo Lenti; Nicola Aronico; Paolo Giuffrida; Valentina Antoci; Giovanni Santacroce; Alessandro Vanoli; Catherine Klersy; Gino Roberto Corazza; Antonio Di Sabatino
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.